Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Completed 2Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Leukemia, Myeloid, Chronic-Phase 2Bronchiolitis Obliterans Syndrome 2Recurrence 1Leukemia, Myeloid 1Leukemia 1Hematologic Diseases 1Advanced Solid Tumors 1

Interventions

tofacitinib 6ibrutinib 6Imatinib Mesylate 5ofatumumab 4Rituximab 4nilotinib 3ruxolitinib 2bosutinib 2asciminib 2Pentostatin 2Oxycodone 2Naloxone 2KW-2478 2Dasatinib 2ziconotide 1sodium luminolate 1posaconazole 1pegfilgrastim 1oblimersen 1obinutuzumab 1montelukast 1mocetinostat 1lonafarnib 1ixekizumab 1fludarabine 1fenebrutinib 1canakinumab 1baricitinib 1abexinostat 1Voriconazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Bronchiolitis Obliterans Syndrome × asciminib × Clear all
NCT06427811 2026-04-17

ASC4INDIA

Novartis

Phase 4 Completed
85 enrolled
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04795427 2025-04-18

Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors

Novartis

Phase 2 Completed
84 enrolled
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡